Takeda’s Qdenga dengue vaccine approved for India, private rollout eyed in H1 2027
Qdenga is approved for people aged 4–60 and is expected to enter private healthcare channels in the first half of 2027. The two-dose dengue vaccine may initially be imported from Germany and is estimated to cost Rs 3,000–6,000 per dose.
India’s drug regulator approved Takeda’s Qdenga dengue vaccine. It is expected to launch through private healthcare settings in the first half of 2027, initially imported from Germany, with an estimated price of Rs 3,000-6,000 per dose.
Why this matters
No related recent signals are listed; the India approval sets up a planned H1 2027 private healthcare rollout for Qdenga.
Retail-brand signals are accelerating, up 347500% QoQ.